The Retrospective Clinical Study of Extranodal Diffuse Large B-Cell Lymphoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,023
- 试验地点
- 1
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies in real-world populations.
详细描述
DLBCL is a highly common aggressive non-Hodgkin's lymphoma. For specific extranodal sites of DLBCL, traditional chemotherapy protocols often cannot provide satisfactory results for patients. The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, including the distribution of involved sites (such as central nervous system, testes, skin, breast, gastrointestinal tract, etc.), prognosis of diffuse large B-cell lymphoma with involvement of different extranodal sites, genetic mutation characteristics, correlation with molecular subtypes, impact of different treatment regimens on efficacy, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies in real-world populations.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years (including 18 years).
- •Pathologically diagnosed with diffuse large B-cell lymphoma according to the 2016 WHO classification, including non-specific types and various special subtypes.
- •Newly diagnosed DLBCL with involvement of extranodal organs.
- •Patients who have received clinical treatment for lymphoma.
- •5.Patients with measurable lesions, including at least one effective efficacy assessment.
排除标准
- •Patients receiving supportive care only.
- •Patients who cannot obtain effective efficacy assessment data.
结局指标
主要结局
Overall Survival (OS)
时间窗: Time Frame: Baseline up to data cut-off (up to approximately 1 year)
Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.
Progression Free Survival (PFS)
时间窗: Time Frame: Baseline up to data cut-off (up to approximately 1 year)
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
次要结局
- Clinical characteristics form(Baseline up to data cut-off (up to approximately 1 year))
研究者
Zhao Weili
First Deputy Director, Hematology Department
Ruijin Hospital